Shots: The approval is based on P-III MEDALIST study involves assessing ReblozyL vs PBO in a ratio (2:1) in adult patients with very low- to intermediate-risk MDS-RS requiring regular RBC […]readmore
Tags : Myelodysplastic Syndromes
Shots: The US FDA has granted BTD for APR-246 in combination with azacitidine to treat myelodysplastic syndromes (MDS) with a susceptible TP53 mutation The BTD supports the development program for […]readmore
Shots: The BLA acceptance follows safety and efficacy data from two P-III MEDALIST and BELIEVE study result assessing Luspatercept vs PBO to treat anemia associated with MDS and beta-thalassemia, with […]readmore